CorMedix (NASDAQ:CRMD) Issues Quarterly Earnings Results

Posted by on May 14th, 2026

CorMedix (NASDAQ:CRMD – Get Free Report) announced its quarterly earnings results on Thursday. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.35 by $0.08, Zacks reports. The company had revenue of $127.43 million for the quarter, compared to analyst estimates of $104.96 million. CorMedix had a net margin of 52.31% and a return on equity of 52.30%. The firm’s revenue was up 226.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.30 earnings per share.

Here are the key takeaways from CorMedix’s conference call:

  • CorMedix reported Q1 2026 net revenue of $127.4 million and adjusted EBITDA of $70 million, both reflecting strong execution and ahead of expectations. Management said the quarter benefited from durable DefenCath demand and the full-quarter contribution from the Melinta portfolio.
  • The company raised full-year guidance, increasing net revenue to $325 million-$345 million and adjusted EBITDA to $115 million-$135 million. It also lifted DefenCath guidance to $175 million-$195 million, citing continued utilization strength.
  • Management expects DefenCath revenue variability in the second half of 2026 as TDAPA reimbursement expires and the product moves to the post-TDAPA add-on phase. The company expects a higher net selling price in 2027 and said its near-term priority is to maintain or grow patient utilization.
  • Preliminary top-line results from the ReSPECT phase III study showed REZZAYO met its primary endpoint and was non-inferior to standard antifungal therapy, with a favorable safety profile. CorMedix said the data support pursuing an sNDA submission in the second half of 2026 and a potential commercial launch in 2027.
  • The Nutri-Guard TPN study is progressing slowly, with enrollment at only about one-third of the level needed for the interim analysis and completion now trending toward 2028. CorMedix plans to add sites and seek an FDA protocol amendment to broaden eligibility and speed enrollment.

CorMedix Stock Performance

CRMD stock traded up $0.41 during trading on Thursday, hitting $7.91. The company had a trading volume of 3,916,095 shares, compared to its average volume of 2,002,427. The firm has a market cap of $620.38 million, a PE ratio of 3.95 and a beta of 1.46. CorMedix has a 1-year low of $6.13 and a 1-year high of $17.43. The firm has a 50-day moving average price of $7.07 and a 200-day moving average price of $8.69. The company has a quick ratio of 1.94, a current ratio of 2.11 and a debt-to-equity ratio of 0.36.

Hedge Funds Weigh In On CorMedix

A number of large investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of CorMedix by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,987 shares of the company’s stock valued at $222,000 after buying an additional 1,631 shares during the period. Legal & General Group Plc grew its holdings in CorMedix by 17.1% during the second quarter. Legal & General Group Plc now owns 62,620 shares of the company’s stock worth $771,000 after acquiring an additional 9,155 shares during the period. Rhumbline Advisers raised its position in CorMedix by 13.9% in the second quarter. Rhumbline Advisers now owns 92,905 shares of the company’s stock worth $1,145,000 after acquiring an additional 11,340 shares in the last quarter. Russell Investments Group Ltd. raised its position in CorMedix by 22.2% in the second quarter. Russell Investments Group Ltd. now owns 6,553 shares of the company’s stock worth $81,000 after acquiring an additional 1,190 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in CorMedix in the second quarter valued at $199,000. 34.18% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

CRMD has been the subject of several research reports. Leerink Partners boosted their target price on CorMedix from $13.00 to $14.00 and gave the company an “outperform” rating in a report on Tuesday, April 28th. Citizens Jmp reissued a “market outperform” rating and issued a $19.00 target price on shares of CorMedix in a report on Tuesday, April 28th. HC Wainwright reduced their target price on CorMedix from $18.00 to $13.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Zacks Research downgraded CorMedix from a “hold” rating to a “strong sell” rating in a report on Tuesday, February 10th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $14.00 target price (up from $13.00) on shares of CorMedix in a report on Tuesday, April 28th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, CorMedix currently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Check Out Our Latest Stock Report on CorMedix

CorMedix declared that its Board of Directors has initiated a stock buyback plan on Monday, February 2nd that authorizes the company to repurchase $75.00 million in outstanding shares. This repurchase authorization authorizes the company to buy up to 12.3% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

Trending Headlines about CorMedix

Here are the key news stories impacting CorMedix this week:

  • Positive Sentiment: CorMedix reported Q1 2026 adjusted earnings of $0.43 per share, ahead of the $0.35 consensus estimate, while revenue of $127.4 million also beat expectations of $105.0 million. Article Title
  • Positive Sentiment: The company said net revenue rose 226.1% year over year, underscoring rapid growth and strong demand. Article Title
  • Positive Sentiment: CorMedix raised FY 2026 revenue guidance to $325 million-$345 million, above Wall Street’s $306.6 million estimate, which typically supports investor confidence in future results. Article Title
  • Neutral Sentiment: The stock also saw unusual options activity, with call volume running above normal, suggesting traders were positioning for more upside around the earnings release.

CorMedix Company Profile

(Get Free Report)

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.

Read More

Earnings History for CorMedix (NASDAQ:CRMD)

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.